Network Meta-analysis of Chinese patent medicines in treatment of coronary heart disease complicated with heart failure
The efficacy and safety of different Chinese patent medicines in the treatment of coronary heart disease complicated with heart failure were evaluated by network Meta-analysis.The randomized controlled trial(RCT)of Chinese patent medicines for coronary heart disease complicated with heart failure was retrieved from CNKI,Wanfang,VIP,SinoMed,PubMed,Web of Science,EMbase,and Cochrane Library with the time interval from inception to July 5,2023.The quality of the included RCT was evaluated by the Co-chrane′s risk of bias assessment tool,and a network Meta-analysis was performed in Stata 16.0.Finally,a total of 82 RCTs were in-cluded,involving 9 298 patients and 11 Chinese patent medicines.Network Meta-analysis yielded the following results based on the surface under the cumulative ranking curve(SUCRA).①In terms of improving the clinical response rate,the top three interventions were Qishen Yiqi Dripping Pills + conventional western medicine,Zhenyuan Capsules + conventional western medicine,and Tongxin-luo Capsules + conventional western medicine.② In terms of increasing left ventricular ejection fraction(LVEF),the top three inter-ventions were Shexiang Baoxin Pills + conventional western medicine,Compound Danshen Dripping Pills + conventional western medi-cine,and Tongxinluo Capsules + conventional western medicine.③ In terms of reducing left ventricular end-diastolic diameter(LVEDD),the top three interventions were Shexiang Tongxin Dripping Pills + conventional western medicine,Tongxinluo Capsules + conventional western medicine,and Shexiang Baoxin Pills + conventional western medicine.④ In terms of reducing N-terminal pro-brain natriuretic peptide(NT-proBNP),the top three interventions were Shexiang Baoxin Pills + conventional western medicine,Qi-shen Yiqi Dripping Pills + conventional western medicine,and Compound Danshen Dripping Pills + conventional western medicine.⑤ In terms of reducing hyper-sensitive C-reactive protein(hs-CRP),the top three interventions were Naoxintong Capsules + conven-tional western medicine,Shexiang Baoxin Pills + conventional western medicine,and Compound Danshen Dripping Pills + conventional western medicine.⑥ In terms of increasing the distance of the six-minute walking trail(6MWT),the top three interventions were Zhen-yuan Capsules + conventional western medicine,Qili Qiangxin Capsules + conventional western medicine,and Qishen Yiqi Dripping Pills + conventional western medicine.The results showed that Chinese patent medicines combined with conventional western medicine can effectively improve the clinical response rate,LVEF,and 6MWT and reduce LVEDD,NT-proBNP,and hs-CRP.However,due to the overall low quality of the articles included and the few articles of some Chinese patent medicines,direct comparison between diffe-rent Chinese patent medicines remains to be carried out and the results need to be further verified.
Chinese patent medicinecoronary heart diseaseheart failurenetwork Meta-analysis
NETL
NSTL
万方数据
维普
